Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 9/20 | 0.53 |
| ▸ | MAPK13 | O15264 | 7/20 | 0.53 |
| ▸ | MAPK12 | P53778 | 7/20 | 0.53 |
| ▸ | MAPK11 | Q15759 | 7/20 | 0.53 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | BRAF | P15056 | 2/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5005410 | 0.88 | MAPK14 (0.53) | MAPK14MAPK13MAPK12MAPK11NTRK1 | |
| SCHEMBL5008408 | 0.82 | MAPK14 (0.53) | MAPK14MAPK13MAPK12MAPK11NTRK1 | |
| SCHEMBL5012010 | 0.82 | MAPK14 (0.55) | MAPK14MAPK13MAPK12MAPK11NTRK1 | |
| SCHEMBL5010746 | 0.82 | MAPK14 (0.53) | MAPK14MAPK13MAPK12MAPK11NTRK1 | |
| SCHEMBL5008471 | 0.81 | MAPK14 (0.61) | MAPK14MAPK13MAPK12MAPK11NTRK1 | |
| SCHEMBL5012222 | 0.80 | ADORA1 (0.62) | MAPK14MAPK13MAPK12MAPK11NTRK1 | |
| SCHEMBL5010659 | 0.80 | MAPK14 (0.64) | MAPK14MAPK13MAPK12MAPK11NTRK1 | |
| SCHEMBL5008532 | 0.80 | MAPK14 (0.47) | MAPK14MAPK13MAPK12MAPK11ADORA1 | |
| SCHEMBL5008388 | 0.80 | MAPK14 (0.53) | MAPK14MAPK13MAPK12MAPK11BRAF | |
| SCHEMBL3305011 | 0.80 | MAPK14 (0.45) | MAPK14MAPK13MAPK12MAPK11NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080064734-A1 | Anilinopyrazole derivatives useful for the treatment of diabetes | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-03-13 | — | — | US | disclosed |
| US-20080064734-A1 | Anilinopyrazole derivatives useful for the treatment of diabetes | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-03-13 | — | — | US | disclosed |
| US-20080064734-A1 | Anilinopyrazole derivatives useful for the treatment of diabetes | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-03-13 | — | — | US | disclosed |
| US-20080009531-A1 | 5-Anilino-4-Heteroarylpyrazole Derivatives Useful for the Treatment of Diabetes | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-01-10 | — | — | US | disclosed |
| US-20080009531-A1 | 5-Anilino-4-Heteroarylpyrazole Derivatives Useful for the Treatment of Diabetes | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-01-10 | — | — | US | disclosed |
| US-20080009531-A1 | 5-Anilino-4-Heteroarylpyrazole Derivatives Useful for the Treatment of Diabetes | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-01-10 | — | — | US | disclosed |
| US-7265144-B2 | Anilinopyrazole derivatives useful for the treatment of diabetes | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-09-04 | — | — | US | disclosed |
| US-7265144-B2 | Anilinopyrazole derivatives useful for the treatment of diabetes | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-09-04 | — | — | US | disclosed |
| US-7265144-B2 | Anilinopyrazole derivatives useful for the treatment of diabetes | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-09-04 | — | — | US | disclosed |
| US-20040157904-A1 | Anilinopyrazole derivatives useful for the treatment of diabetes | BAYER PHARMACEUTICALS CORPORATION | 2004-08-12 | — | — | US | disclosed |
| WO-2004050651-A1 | ANILINOPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES | BAYER PHARMACEUTICALS CORPORATION (US) | 2004-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064734-A1 | Anilinopyrazole derivatives useful for the treatment of diabetes | IAPP, GLP1R, GPR119 | MAPK14 1938/4885MAPK13 885/4885MAPK12 1488/4885 |
| US-20040157904-A1 | Anilinopyrazole derivatives useful for the treatment of diabetes | IAPP, GLP1R, GPR119 | MAPK14 1938/4885MAPK13 885/4885MAPK12 1488/4885 |
| US-20080009531-A1 | 5-Anilino-4-Heteroarylpyrazole Derivatives Useful for the Treatment of Diabetes | GPR119, IAPP, GLP1R | MAPK14 2856/4885MAPK13 2111/4885MAPK12 2689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.